Knight Therapeutics Inc.
(MENAFN- Baystreet) 10:31 AM EST - Knight Therapeutics Inc. : Announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. Minjuvi® in combination with lenalidomide, followed by Minjuvi® monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT). Knight Therapeutics Inc.
shares T are trading up $0.02 at $6.03.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Japan Buy Now Pay Later Market Size To Surpass USD 145.5 Billion By 2033 CAGR Of 22.23%
- BTCC Summer Festival 2025 Unites Japan's Web3 Community
- GCL Subsidiary, 2Game Digital, Partners With Kucoin Pay To Accept Secure Crypto Payments In Real Time
- Smart Indoor Gardens Market Growth: Size, Trends, And Forecast 20252033
- Nutritional Bar Market Size To Expand At A CAGR Of 3.5% During 2025-2033
- Pluscapital Advisor Empowers Traders To Master Global Markets Around The Clock
More Story
Comments
No comment